Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther Ads (NQ: ADAP )

4.680 USD -0.250 (-5.07%)
Official Closing Price Updated: 5:50 PM EDT, Apr 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Adaptimmune Ther Ads

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
58 Biggest Movers From Yesterday
Gainers JetPay Corporation (NASDAQ: JTPY) shares climbed 133.96 percent to close at $4.96 on Monday after the company announced ... 
Tags AVEO KDMN IMGN
From Benzinga
Mid-Afternoon Market Update: JetPay Climbs On Acquisition News; Opus Bank Shares Slide
Toward the end of trading Monday, the Dow traded down 0.34 percent to 25,358.24 while the NASDAQ climbed 0.31 percent to 7,471.89. The ... 
Tags News Global Benzinga
From Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Gainers JetPay Corporation (NASDAQ: JTPY) shares jumped 135 percent to $4.98 after the company announced it would be acquired for ... 
Tags Benzinga Movers & Shakers LYL
From Benzinga
RSI Alert: Adaptimmune Therapeutics (ADAP) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and... 
From GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arsanis, Inc.... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs
Here are a few catalysts that can dictate the directional moves of biotech stocks in the upcoming week: Conferences European ... 
Tags Health Care Market News AGEN
From Benzinga
Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced further details about two poster presentations at the upcoming ESMO congress, as... 
From GlobeNewswire News Releases
Best And Worst ADRs - Monday, Sept. 24
The best-rated sectors in our ADR universe are healthcare and basic materials. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Which 3 Stocks Are Insiders Buying Like Crazy?
Let’s take a closer look at GTT Communications, Adaptimmune Therapeutics and Six Flags Entertainment. 
Tags Stocks / Equities
From Blogs - TalkMarkets
Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its... 
From GlobeNewswire News Releases
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management... 
From GlobeNewswire News Releases
44 Biggest Movers From Yesterday
Gainers Alliance MMA, Inc. (NASDAQ: AMMA) shares jumped 110.32 percent to close at $0.42 on Friday after the company announced ... 
Tags REED GERN CNAT
From Benzinga
Adaptimmune Therapeutics Breaks Above 200-Day Moving Average - Bullish for ADAP
In trading on Friday, shares of Adaptimmune Therapeutics PLC (ADAP) crossed above their 200 day moving average of $9.97, changing hands as high as $10.50 per share. Adaptimmune Therapeutics PLC shares... 
Tags Stocks
From Market News Video
Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics — Discovering Underlying Fac
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NEXEO SOLUTIONS... 
From GlobeNewswire News Releases
Analysts Forecast 14% Upside For The Holdings of ADRU
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a favorable review of safety data from the second dose cohort of patients who received one... 
From GlobeNewswire News Releases
Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2018, and provided a business update. 
From GlobeNewswire News Releases
Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Second Quarter 2018 and provide a general business update before the U.S.... 
From GlobeNewswire News Releases
GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK
GlaxoSmithKline plc and Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the transition of the development program for GSK3377794 (GSK ‘794), an... 
From GlobeNewswire News Releases
Free Technical Briefing on Biotech Stocks -- ARCA biopharma, Achieve Life Sciences, Acorda Therapeutics, and Adaptimmune Therapeutics
If you want a free Stock Review on ABIO, ACHV, ACOR, and ADAP sign up now at https://stocktraderreport.com/registration/. On Wednesday, July 18, 2018, US markets saw six out of nine sectors finishing... 
From PR Newswire
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a ... 
Tags MS PFE Market News
From Benzinga
28 Stocks Moving In Wednesday's Pre-Market Session
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) shares rose 27.1 percent to $15.43 in pre-market trading after reporting interim ... 
Tags ASYS UAL UUUU
From Benzinga
Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced favorable review of safety data from the second dose cohort of patients who received one billion... 
From GlobeNewswire News Releases
Analysts Forecast 13% Gains Ahead For ADRU
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The Math Shows ADRD Can Go To $26
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Self?renewing, and Capable of Persistent Anti-Tumor Effects
Data indicate that self-renewing pools of SPEAR T-cells can produce a continuous supply of effector cells capable of mediating sustained antitumor effects 
From GlobeNewswire News Releases
Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the independent safety review committee has recommended dose escalation in the MAGE-A4... 
From GlobeNewswire News Releases
Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented a safety update from its two ongoing pilot studies with SPEAR T-cells targeting MAGE-A10 in non-small... 
From GlobeNewswire News Releases
The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines
A few FDA approvals and the impending 2018 American Society of Clinical Oncology annual meeting gave some impetus to the biotech space ... 
Tags IDRA CDTX IMGN
From Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.